GLP-1 type medications are powerful tools that work by reducing your appetite and helping you feel fuller for longer, making it easier to manage your weight
The SELECT trial specifically demonstrated that semaglutide reduces major adverse cardiovascular events by 20% in patients with established cardiovascular disease, regardless of diabetes status
As a broad-spectrum ROS scavenger, self-assembled ultrasmall nanoparticles (FGP nanoparticles) composed of iron ions, gallic acid and polyvinylpyrrolidone can alleviate mouse AKI induced by glycerol and cisplatin (Zhang et al., 2021b)
They are not approved for human or veterinary use and are not intended to diagnose, treat, cure, or prevent any disease
Schlottmann, F., Dreifuss, N